Co-Authors
This is a "connection" page, showing publications co-authored by Julie Chao and Lee Chao.
Connection Strength
19.462
-
Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2018; 2018:4138560.
Score: 0.689
-
Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway. Oxid Med Cell Longev. 2017; 2017:5262958.
Score: 0.644
-
Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. Biol Chem. 2017 11 27; 398(12):1309-1317.
Score: 0.642
-
Role of Kallistatin Treatment in Aging and Cancer by Modulating miR-34a and miR-21 Expression. Oxid Med Cell Longev. 2017; 2017:5025610.
Score: 0.624
-
Kallistatin suppresses cancer development by multi-factorial actions. Crit Rev Oncol Hematol. 2017 May; 113:71-78.
Score: 0.611
-
Protective Role of Kallistatin in Vascular and Organ Injury. Hypertension. 2016 09; 68(3):533-41.
Score: 0.584
-
Kallikrein-kinin in stem cell therapy. World J Stem Cells. 2014 Sep 26; 6(4):448-57.
Score: 0.515
-
Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res. 2014; 69:37-57.
Score: 0.490
-
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 2010 Apr; 391(4):345-55.
Score: 0.378
-
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.
Score: 0.339
-
Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension. 2007 Mar; 49(3):490-7.
Score: 0.302
-
Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 2006 Dec; 17(12):1201-13.
Score: 0.300
-
The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem. 2006 Jun; 387(6):665-75.
Score: 0.290
-
Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
Score: 0.288
-
Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol. 2005 May; 90(3):291-8.
Score: 0.263
-
Adenovirus-mediated gene transfer for cardiovascular and renal diseases. Methods Enzymol. 2002; 346:247-63.
Score: 0.213
-
Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides. 2001 Nov; 22(11):1731-7.
Score: 0.211
-
Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem. 2001 Jan; 382(1):15-21.
Score: 0.199
-
Gene therapy for hypertension: a review of potential targets. BioDrugs. 1999 Jan; 11(1):43-53.
Score: 0.173
-
Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice. J Am Heart Assoc. 2018 11 06; 7(21):e009562.
Score: 0.171
-
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int. 1998 Oct; 54(4):1250-60.
Score: 0.170
-
Kallistatin attenuates endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway. J Cell Mol Med. 2018 09; 22(9):4387-4398.
Score: 0.168
-
Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther. 1998 Jan 01; 9(1):21-31.
Score: 0.162
-
Kallistatin in blood pressure regulation transgenic and somatic gene delivery studies. Trends Cardiovasc Med. 1997 Nov; 7(8):307-11.
Score: 0.160
-
New experimental evidence for a role of tissue kallikrein in hypertension. Nephrol Dial Transplant. 1997 Aug; 12(8):1569-74.
Score: 0.157
-
Kallistatin is a potent new vasodilator. J Clin Invest. 1997 Jul 01; 100(1):11-7.
Score: 0.156
-
Kallikrein gene therapy: a new strategy for hypertensive diseases. Immunopharmacology. 1997 Jun; 36(2-3):229-36.
Score: 0.155
-
Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol. 1997 Jun; 75(6):750-6.
Score: 0.155
-
Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Pharmacol Res. 1997 Jun; 35(6):517-22.
Score: 0.155
-
Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway. Aging Cell. 2017 08; 16(4):837-846.
Score: 0.155
-
Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med. 1996 Jun; 127(6):612-20.
Score: 0.145
-
Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther. 1996 May 20; 7(8):901-11.
Score: 0.144
-
Tissue kallikrein inhibitors in mammals. Immunopharmacology. 1996 May; 32(1-3):67-72.
Score: 0.144
-
Functional analysis of human tissue kallikrein in transgenic mouse models. Hypertension. 1996 Mar; 27(3 Pt 2):491-4.
Score: 0.142
-
Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. Exp Cell Res. 2016 Jan 15; 340(2):305-14.
Score: 0.141
-
Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler. 1995 Dec; 376(12):705-13.
Score: 0.140
-
Kallistatin inhibits TGF-?-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp Cell Res. 2015 Sep 10; 337(1):103-10.
Score: 0.136
-
Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care. 2015 May 01; 19:200.
Score: 0.134
-
Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc. 2014 Sep 18; 3(5):e001194.
Score: 0.129
-
Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014 Jun; 142(2):216-26.
Score: 0.126
-
Regulation of kininogen gene expression and localization in the lung after monocrotaline-induced pulmonary hypertension in rats. Proc Soc Exp Biol Med. 1993 Jun; 203(2):243-50.
Score: 0.118
-
Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J. 2013; 77(8):2134-44.
Score: 0.117
-
Kallistatin antagonizes Wnt/?-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem. 2013 Jul; 379(1-2):295-301.
Score: 0.117
-
Tissue kallikrein is related to the severity of coronary artery disease. Clin Chim Acta. 2013 Aug 23; 423:90-8.
Score: 0.117
-
Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest. 2013 May; 93(5):577-91.
Score: 0.116
-
Screening of complementary DNA library using radiolabeled antigen. Methods Enzymol. 1993; 217:325-35.
Score: 0.114
-
Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol. 2012 Oct 15; 303(8):F1230-8.
Score: 0.111
-
Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther. 2012 Aug; 23(8):859-70.
Score: 0.109
-
Expression of kallikrein-binding protein and alpha 1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. Agents Actions Suppl. 1992; 38 ( Pt 1):174-81.
Score: 0.107
-
Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem. 1990 Sep 25; 265(27):16394-401.
Score: 0.098
-
Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol. 2010 Nov; 299(5):H1419-27.
Score: 0.097
-
Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem. 2010 Jul; 391(7):803-12.
Score: 0.096
-
Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension. 2010 Aug; 56(2):260-7.
Score: 0.096
-
Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol. 2010 Apr; 298(4):F1033-40.
Score: 0.093
-
Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol. 2010 Mar; 298(3):H1048-54.
Score: 0.093
-
Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. J Biol Chem. 2009 Dec 18; 284(51):35471-8.
Score: 0.093
-
A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res. 2010 Feb 01; 316(3):376-89.
Score: 0.092
-
Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol. 2009 Sep; 297(3):H1040-7.
Score: 0.090
-
Structural analysis of a rat renal kallikrein gene. Adv Exp Med Biol. 1989; 247A:73-80.
Score: 0.087
-
Sex dimorphism and estrogen regulation of kininogens in rat serum, adrenal gland and kidney. Adv Exp Med Biol. 1989; 247B:297-303.
Score: 0.087
-
Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1735-43.
Score: 0.085
-
Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest. 2008 Nov; 88(11):1157-66.
Score: 0.085
-
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res. 2008 Dec 01; 80(3):354-64.
Score: 0.084
-
Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
Score: 0.084
-
A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. J Hypertens. 1988 Jul; 6(7):551-7.
Score: 0.084
-
Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008 Jun; 389(6):725-30.
Score: 0.083
-
Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008 May; 51(5):1358-65.
Score: 0.082
-
Tissue distribution and kininogen gene expression after acute-phase inflammation. Biochim Biophys Acta. 1988 Mar 17; 964(3):329-39.
Score: 0.082
-
Circulating autoantibodies to mammalian tissue kallikreins. Proc Soc Exp Biol Med. 1988 Mar; 187(3):320-6.
Score: 0.082
-
Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci. 2008 Apr; 102(2):433-43.
Score: 0.081
-
Identification and expression of kallikrein gene family in rat submandibular and prostate glands using monoclonal antibodies as specific probes. Biochim Biophys Acta. 1987 Dec 08; 910(3):233-9.
Score: 0.080
-
Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 2008 Jan 16; 82(3-4):156-65.
Score: 0.080
-
Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol. 2007 Nov; 34(11):2171-6.
Score: 0.080
-
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail. 2007 Sep; 13(7):588-96.
Score: 0.079
-
Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007 Jul; 28(7):1383-9.
Score: 0.077
-
Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept. 2007 Apr 05; 140(1-2):12-20.
Score: 0.075
-
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007 Jan 01; 73(1):130-42.
Score: 0.074
-
Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther. 2006 May; 17(5):545-55.
Score: 0.072
-
Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr; 47(4):752-61.
Score: 0.071
-
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb; 17(2):206-19.
Score: 0.071
-
Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
Score: 0.070
-
Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol. 2006 Feb; 197(2):521-30.
Score: 0.070
-
Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F622-31.
Score: 0.067
-
Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes. 2005 May; 54(5):1573-80.
Score: 0.067
-
Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005 Apr 08; 76(21):2457-71.
Score: 0.067
-
Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 2005 Apr; 52(4):1319-24.
Score: 0.067
-
Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
Score: 0.065
-
Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004 Dec; 15(12):1243-54.
Score: 0.065
-
Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 2004 Aug; 66(2):722-32.
Score: 0.064
-
Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb; 43(2):452-9.
Score: 0.061
-
Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension. 2004 Jan; 43(1):109-16.
Score: 0.061
-
Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1479-88.
Score: 0.059
-
Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1506-14.
Score: 0.059
-
Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol. 2003 06; 284(6):C1604-13.
Score: 0.059
-
Adrenomedullin gene delivery inhibits neointima formation in rat artery after balloon angioplasty. Regul Pept. 2003 Apr 15; 112(1-3):115-20.
Score: 0.058
-
Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats. Am J Physiol Regul Integr Comp Physiol. 2003 Apr; 284(4):R1031-6.
Score: 0.057
-
Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2002 Aug 01; 22(8):1279-85.
Score: 0.055
-
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol. 2001 Nov; 159(5):1797-805.
Score: 0.053
-
Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2001 Jun; 280(6):F964-71.
Score: 0.051
-
Identification of a major heparin-binding site in kallistatin. J Biol Chem. 2001 Jan 12; 276(2):1276-84.
Score: 0.050
-
A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J Biol Chem. 2000 Dec 22; 275(51):40371-7.
Score: 0.050
-
Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J Biol Chem. 2000 Dec 08; 275(49):38457-66.
Score: 0.050
-
Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 2000 Dec; 36(6):995-1001.
Score: 0.049
-
Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther. 2000 Sep 01; 11(13):1817-27.
Score: 0.049
-
Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension. 2000 Sep; 36(3):364-70.
Score: 0.049
-
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000 Aug; 58(2):730-9.
Score: 0.048
-
Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta. 2000 Jun 15; 1479(1-2):237-46.
Score: 0.048
-
Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res. 2000 Mar 03; 86(4):418-24.
Score: 0.047
-
Enhanced renal function in bradykinin B(2) receptor transgenic mice. Am J Physiol Renal Physiol. 2000 Mar; 278(3):F484-91.
Score: 0.047
-
Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
Score: 0.046
-
Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology. 1999 Oct 15; 44(1-2):57-65.
Score: 0.046
-
Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology. 1999 Oct 15; 44(1-2):137-43.
Score: 0.046
-
Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. Clin Exp Hypertens. 1999 Oct; 21(7):1145-60.
Score: 0.046
-
Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke. 1999 Sep; 30(9):1925-31; discussion 1931-2.
Score: 0.045
-
Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension. 1999 Aug; 34(2):164-70.
Score: 0.045
-
Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats. Nephrol Dial Transplant. 1999 Jun; 14(6):1376-84.
Score: 0.045
-
Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. Am J Physiol. 1999 03; 276(3):F476-84.
Score: 0.044
-
Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem. 1999 Feb; 47(2):221-8.
Score: 0.044
-
Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999 Jan; 33(1 Pt 2):219-24.
Score: 0.043
-
Molecular cloning and expression of rat bradykinin B1 receptor. Biochim Biophys Acta. 1998 Nov 08; 1442(2-3):177-85.
Score: 0.043
-
Cellular localization of kallistatin and tissue kallikrein in human pancreas and salivary glands. Histochem Cell Biol. 1998 Nov; 110(5):477-84.
Score: 0.043
-
Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther. 1998 Jul 01; 9(10):1429-38.
Score: 0.042
-
Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 1998 May; 53(5):1305-13.
Score: 0.041
-
Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension. 1998 May; 31(5):1104-10.
Score: 0.041
-
Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun. 1998 Mar 17; 244(2):449-54.
Score: 0.041
-
Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem. 1998 Jan 30; 273(5):2784-91.
Score: 0.041
-
Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res. 1997 Dec; 20(4):269-77.
Score: 0.040
-
Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat. Am J Physiol. 1997 11; 273(5):F783-9.
Score: 0.040
-
Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther. 1997 Oct 10; 8(15):1753-61.
Score: 0.040
-
Molecular cloning and expression of rat kallistatin gene. Biochim Biophys Acta. 1997 Sep 12; 1353(3):277-86.
Score: 0.040
-
Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997 Sep; 30(3 Pt 1):307-13.
Score: 0.039
-
Tissue-specific expression and promoter analyses of the human tissue kallikrein gene in transgenic mice. Biochem J. 1997 Jul 01; 325 ( Pt 1):111-6.
Score: 0.039
-
Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmacology. 1997 Jun; 36(2-3):221-7.
Score: 0.039
-
DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene. Hum Genet. 1997 Jun; 99(6):727-34.
Score: 0.039
-
Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS One. 2017; 12(5):e0178387.
Score: 0.039
-
Expression and localization of human kallistatin in rat submandibular gland after intracapsular gene injection. Biochem Biophys Res Commun. 1997 Feb 13; 231(2):494-8.
Score: 0.038
-
Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther. 1997 Feb 10; 8(3):341-7.
Score: 0.038
-
Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension. 1997 Jan; 29(1 Pt 2):488-93.
Score: 0.038
-
Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci. 1997; 60(17):1431-5.
Score: 0.038
-
Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J Biol Chem. 1996 Nov 01; 271(44):27590-4.
Score: 0.037
-
High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exp Hypertens. 1996 Nov; 18(8):975-93.
Score: 0.037
-
Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res. 1996 Nov; 15(11):1117-23.
Score: 0.037
-
High-salt diet upregulates kininogen and downregulates tissue kallikrein expression in Dahl-SS and SHR rats. Am J Physiol. 1996 Oct; 271(4 Pt 2):F824-30.
Score: 0.037
-
Expression and cellular localization of tissue kallikrein-kinin system in human adrenal gland. Am J Physiol. 1996 Sep; 271(3 Pt 2):F709-16.
Score: 0.037
-
Identification and characterization of two promoters of rat kallikrein-binding protein gene. Biochim Biophys Acta. 1996 Jul 17; 1307(3):285-93.
Score: 0.037
-
Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. Am J Physiol. 1996 Jul; 271(1 Pt 2):F78-86.
Score: 0.036
-
Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp Eye Res. 1996 Jul; 63(1):19-26.
Score: 0.036
-
Cellular localization of bradykinin B1 receptor mRNA in the human kidney. Immunopharmacology. 1996 Jun; 33(1-3):151-6.
Score: 0.036
-
Cellular localization of low-molecular-weight kininogen and bradykinin B2 receptor mRNAs in human kidney. Am J Physiol. 1996 Jun; 270(6 Pt 2):F919-26.
Score: 0.036
-
High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice. Immunopharmacology. 1996 May; 32(1-3):105-7.
Score: 0.036
-
Structure and chromosomal localization of the human prostasin (PRSS8) gene. Genomics. 1996 Mar 15; 32(3):334-40.
Score: 0.036
-
Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. Genomics. 1996 Jan 01; 31(1):51-7.
Score: 0.035
-
Regulatory elements in the promoter region of the renal kallikrein gene in normotensive vs hypertensive rats. Biochem Biophys Res Commun. 1995 Dec 05; 217(1):113-22.
Score: 0.035
-
Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995 Dec; 26(6 Pt 1):847-53.
Score: 0.035
-
Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int. 1995 Sep; 48(3):690-7.
Score: 0.034
-
Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 2015 Jul 22; 5:12463.
Score: 0.034
-
Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin. Antimicrob Agents Chemother. 2015 Sep; 59(9):5619-30.
Score: 0.034
-
Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J Biol Chem. 1995 Jun 02; 270(22):13483-9.
Score: 0.034
-
Molecular cloning, purification and in situ localization of human colon kallikrein. Biochem J. 1995 Apr 15; 307 ( Pt 2):481-6.
Score: 0.033
-
Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest. 1995 Apr; 95(4):1710-6.
Score: 0.033
-
Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension. 1995 Apr; 25(4 Pt 2):715-9.
Score: 0.033
-
Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem. 1995 Jan 06; 270(1):451-5.
Score: 0.033
-
Cloning, sequence analysis and expression of the gene encoding the mouse bradykinin B2 receptor. Gene. 1994 Nov 18; 149(2):283-8.
Score: 0.033
-
Histopathology of lymphatic tissues in transgenic mice expressing human tissue kallikrein gene. Lab Invest. 1994 Nov; 71(5):680-7.
Score: 0.032
-
Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics. 1994 Sep 15; 23(2):362-9.
Score: 0.032
-
Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4). Genomics. 1994 Sep 15; 23(2):370-8.
Score: 0.032
-
Molecular cloning and sequence analysis of rat bradykinin B2 receptor gene. Biochim Biophys Acta. 1994 Sep 13; 1219(1):171-4.
Score: 0.032
-
Molecular cloning and characterization of a novel kallikrein transcript in colon and its distribution in human tissues. Braz J Med Biol Res. 1994 Aug; 27(8):1829-38.
Score: 0.032
-
Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem. 1994 Jul 22; 269(29):18843-8.
Score: 0.032
-
Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 1994 Feb; 23(2):236-43.
Score: 0.031
-
Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem. 1993 Nov 15; 268(32):24498-505.
Score: 0.030
-
Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection. Antimicrob Agents Chemother. 2013 Nov; 57(11):5366-72.
Score: 0.030
-
Expression and characterization of rat kallikrein-binding protein in Escherichia coli. Biochem J. 1993 Jun 15; 292 ( Pt 3):825-32.
Score: 0.029
-
Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care. 2013 Feb 08; 17(1):R27.
Score: 0.029
-
Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem. 1992 Dec 25; 267(36):25873-80.
Score: 0.029
-
Molecular cloning and characterization of rKlk10, a cDNA encoding T-kininogenase from rat submandibular gland and kidney. Biochemistry. 1992 Nov 10; 31(44):10922-8.
Score: 0.028
-
Specificity determinants of rat tissue kallikrein probed by site-directed mutagenesis. Protein Eng. 1992 Sep; 5(6):569-75.
Score: 0.028
-
Biochemical characterization and substrate specificity of rat prostate kallikrein (S3): comparison with tissue kallikrein, tonin and T-kininogenase. Biochim Biophys Acta. 1992 Jun 24; 1121(3):309-16.
Score: 0.028
-
Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta. 1992 Jun 15; 1131(2):145-51.
Score: 0.028
-
In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J Lab Clin Med. 1992 May; 119(5):514-21.
Score: 0.027
-
Evolution of the kallikrein gene family. Agents Actions Suppl. 1992; 38 ( Pt 1):26-33.
Score: 0.027
-
Comparative studies on P2 specificity of wild-type rat tissue kallikrein, Y99H:W215G mutant and tonin. Agents Actions Suppl. 1992; 38 ( Pt 1):59-65.
Score: 0.027
-
Localization of kallikrein gene family proteases in rat tissues. Agents Actions Suppl. 1992; 38 ( Pt 1):595-602.
Score: 0.027
-
Molecular cloning and sequence analysis of the mouse kallikrein-binding protein gene. Biochim Biophys Acta. 1991 Dec 02; 1129(1):127-30.
Score: 0.026
-
Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem. 1991 Aug 25; 266(24):16029-36.
Score: 0.026
-
Purification and characterization of recombinant tissue kallikrein from Escherichia coli and yeast. Biochem J. 1991 May 15; 276 ( Pt 1):63-71.
Score: 0.026
-
Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer. 2010 May 31; 10:245.
Score: 0.024
-
Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein. Biochem J. 1990 Apr 01; 267(1):79-84.
Score: 0.024
-
Molecular cloning and primary structure of rat alpha 1-antitrypsin. Biochemistry. 1990 Jan 16; 29(2):323-9.
Score: 0.023
-
Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 1990; 15 Suppl 6:S7-16.
Score: 0.023
-
Co-localization of a kallikrein-like serine protease (arginine esterase A) and atrial natriuretic peptide in rat atrium. J Histochem Cytochem. 1989 Dec; 37(12):1913-7.
Score: 0.023
-
Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens. 1989 Nov; 7(11):865-71.
Score: 0.023
-
Sex dimorphism and inflammatory regulation of T-kininogen and T-kininogenase. Biochim Biophys Acta. 1989 Jun 27; 991(3):477-83.
Score: 0.022
-
Characterization of genes encoding rat tonin and a kallikrein-like serine protease. Biochemistry. 1989 Jun 27; 28(13):5334-43.
Score: 0.022
-
Renal kallikrein mRNA localization by in situ hybridization. Kidney Int. 1989 Jun; 35(6):1324-9.
Score: 0.022
-
Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther. 2009 Feb; 20(2):147-58.
Score: 0.022
-
Enhanced specificity in immunoscreening of expression cDNA clones using radiolabeled antigen overlay. Biotechniques. 1989 Jan; 7(1):68-72.
Score: 0.022
-
Human kallistatin, a new tissue kallikrein-binding protein: purification and characterization. Adv Exp Med Biol. 1989; 247B:1-8.
Score: 0.022
-
Comparison of the distribution of tissue kallikrein and esterase A, a kallikrein-like enzyme, in rat kidney using specific monoclonal antibodies. J Histochem Cytochem. 1988 Oct; 36(10):1251-4.
Score: 0.021
-
Molecular cloning and characterization of two rat renal kallikrein genes. Biochemistry. 1988 Sep 20; 27(19):7189-96.
Score: 0.021
-
Immunocytochemical localization of a kallikrein-like serine protease (esterase A) in rat salivary glands. Anat Rec. 1988 May; 221(1):475-81.
Score: 0.021
-
Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays. Mol Cell Endocrinol. 1988 Jan; 55(1):21-31.
Score: 0.020
-
Identification of tonin in brain and exocrine tissues and in the cell-free translation products encoded by the mRNA of these tissues. Biochem J. 1987 Dec 01; 248(2):477-81.
Score: 0.020
-
Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
Score: 0.019
-
Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation. Am J Physiol Renal Physiol. 2006 Sep; 291(3):F567-77.
Score: 0.018
-
Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats. J Gene Med. 2004 Jul; 6(7):786-97.
Score: 0.016
-
Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 Jun; 24(6):1104-10.
Score: 0.016
-
Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension. 2003 Nov; 42(5):1026-33.
Score: 0.015
-
Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation. 2002 Jan 01; 105(1):67-72.
Score: 0.013
-
Kallikrein-binding protein is induced by growth hormone in the dwarf rat. FASEB J. 1999 Oct; 13(13):1839-44.
Score: 0.011
-
Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 1997 Mar; 38(3):658-64.
Score: 0.010
-
Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int. 1992 Apr; 41(4):789-95.
Score: 0.007
-
Identification and characterization of a tissue kallikrein in rat skeletal muscles. Biochem J. 1987 May 01; 243(3):773-8.
Score: 0.005